Combination regimens with PD-1/PD-L1 immune checkpoint inhibitors for gastrointestinal malignancies

Area of Science:

• Oncology
• Immunotherapy
• Gastrointestinal Cancers

Background:

• Gastrointestinal (GI) malignant neoplasms present a significant global health challenge with poor prognoses for advanced cases.
• Programmed cell death protein 1/programmed death-ligand 1 (PD-1/PD-L1) inhibitors offer a frontline treatment but exhibit limitations such as low response rates and acquired resistance when used as monotherapy.

Purpose of the Study:

• To review the limitations of PD-1/PD-L1 inhibitor monotherapies in GI cancers.
• To explore the rationale and clinical applications of combination immunotherapy regimens for GI tumors.

Main Methods:

• Literature review of preclinical and clinical studies.
• Critical discussion of current therapeutic strategies and future directions.

Main Results:

• Monotherapy with PD-1/PD-L1 inhibitors shows suboptimal efficacy in advanced GI cancers.
• Combined immunotherapies demonstrate enhanced therapeutic responses, particularly in the complex tumor microenvironment of GI malignancies.

Conclusions:

• Combination immunotherapy represents a promising next step for treating GI cancers, potentially improving objective response rates and overcoming resistance.
• Further research is necessary to fully elucidate the benefits and optimal application of combined immunological regimens in GI oncology.